Pfizer posts results of Phase 3 gene therapy study in Duchenne Muscular Dystrophy
The study, a Phase 3 long-term safety and efficacy follow-up of fordadistrogene movaparvovec, enrolled 7 participants and was terminated. It began on March 13, 2023, with primary completion on September 24, 2025.
Primary source
ClinicalTrials.gov results record, November 12, 2026
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
Read the source: A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy. clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation